A new study links the Type II Diabetes drug Avandia with a 43% increase in the risk of a heart attack, but the manufacturer of Avandia, Glaxo Smith Klein, continue to deny such claim and claim that such statements are "false and misleading". However, it appears that Avandia, much like Vioxx, was placed on the market without proper warnings for risk of harm to the patient, even though the...